Pediatrics

July 31, 2021

July's month in review features stories related to new diabetes medications, National Kidney Foundation guidance, and FDA news. Check back in during the last weekend of each month for the next Endocrine Month in Review.

July 29, 2021

Announced on July 28, insulin glargine-yfgn (Semglee) becomes the first interchange biosimilar insulin product to receive approval in the FDA's history and is expected to be available by the end of the year.

July 23, 2021

With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.

July 22, 2021

Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.

July 12, 2021

To allow our audience to become more acquainted with our advisory board members, Endocrinology Network will be hosting a special content series highlighting our board members, their practices, and why they were invited to help guide coverage moving forward.

June 22, 2021

Using 24 years of follow-up data from more than 12k adolescents provides insight into the impact of childhood BMI z-scores on risk of adverse health outcomes, including development of diabetes and premature myocardial infarction, in adulthood.

April 06, 2021

An analysis of more than 4 million singleton births indicates children born at an early gestational age were at an increased risk of heart failure at multiple points throughout life when compared to their counterparts not considered preterm births.

March 22, 2021

Zealand Pharma announced the US FDA approved dasiglucagon (Zegalogue) for treatment of severe hypoglycemia in patients with diabetes aged 6 and older and the injectable will be available as both an auto injector and a prefilled syringe.

March 20, 2021

An analysis of 4k transgender youth and 16k propensity-matched controls is providing insight into the increased risk of conditions adversely impacting the cardiometabolic health of these patients.

March 20, 2021

An analysis by investigators from the University of Arkansas suggests children with adrenal insufficiency were 10 times more likely to die from COVID-19 than their counterparts without adrenal insufficiency and COVID-19.